Morphine Effects on the Spontaneous Electroencephalogram in Polydrug Abusers: Correlations with Subjective Self-Reports Robert L

Total Page:16

File Type:pdf, Size:1020Kb

Morphine Effects on the Spontaneous Electroencephalogram in Polydrug Abusers: Correlations with Subjective Self-Reports Robert L NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.3 171 Morphine Effects on the Spontaneous Electroencephalogram in Polydrug Abusers: Correlations with Subjective Self-Reports Robert L. Phillips, Ph.D., Ronald Heming, Ph.D., and Edythe D. London, Ph.D. The spontaneous electroencephalogram (EEG) was on Morphine-Benzedrine Group (MBG) subscale of the recorded after the intramuscular (IM) injection of ARC!. Negative relationships were observed between morphine sulfate (15, 30 mg) or saline (0.9% NaCl). changes in alpha1, and beta2 and scores on the Correlations between changes in EEG spectral power and Pentobarbital Chlorpromazine Alcohol Group (PCAG) subjective self-reports, as measured on subscales of the subscale. The findings indicate that positive subjective Addiction Research Center Inventory (ARC!), were effects of opioids, as measured by the MBG subscale, are evaluated. Morphine increased alphaJ and alpha2 power related to increases in alpha and beta activity and are and theta power, and attenuated the increase in delta associated with reduction of opioid-induced sedation, as power observed after placebo. Positive correlations were measured by the PCAG subscale. found between the change in alpha1, alpha2, beta1, and [Neuropsychopharmacology 10:171-181, 1994] beta2 power in response to 30 mg of morphine and scores KEY WORDS: Electroencephalography; Morphine; Opiate; mal subjects (von Felsinger et al. 1955). Although con­ Reinforcement; Drug abuse siderable information about the actions of opioid drugs in the nervous system exists, little is known about the Thesubjective effectsof opioids have been studied ex­ central mechanisms underlying their effects on mood tensively in human volunteers (Martin 1983). Morphine and feeling state in human subjects. produces a wide variety of effects, including analgesia, Effectsof morphine on the electroencephalogram drowsiness, changes in mood, and mental clouding (EEG) have been tested in several species. In rats, opi­ Gaffe and Martin 1985). In detoxifIed volunteers with oids increase the abundance of low frequencies in the histories of opioid abuse, arousal is produced (Kay et EEG (Wikler 1954; Khazan and Colasanti 1971; Young aI. 1969), mental clouding is less prominent, and posi­ et al. 1980; Young and Khazan 1984, 1986). In the dog, tive effectson mood are more pronounced than in nor- periods of burst-slow activity have been observed (Wik­ ler 1952). Slowing of the EEG is observed in the cat as well (De Andres and Caballero 1989). From the Neuroimaging and Drug Action Section, Neuroscience Opioid-induced slowing of the EEG in human sub­ Branch (RLP, EDL) and the Medical AffairsBranch (RH), Addiction Research Center, National Institute on Drug Abuse, National Institutes jects was &rst discovered by visual observation of EEG ofHealth, Baltimore, Maryland; and Department of Radiology (EDL), tracings (Berger 1937; Andrews 1941, 1943; Gibbs and the Johns Hopkins Medical Institutions and Department of Pharma­ Maltby 1943). Slowing has been de&ned in several ways. cology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore, Maryland. Earlier studies de&ned slowing as a decrease in the dom­ Address correspondence to: Edythe D. London, Ph.D., Chief, inant frequency of the EEG tracings (Fig. la) or as the Neuroimaging and Drug Action Section, NIDA Addiction Research appearance of bursts of slow wave activity (Fig. Ib). Center, P.O. Box 5180, Baltimore, Maryland 21224. Received August 18, 1993; revised December 28, 1993; accepted Later studies using more quantitative methods de&ned January 3, 1994. slowing as a decrease in the alpha frequency (Fig. lc) Published 1994 by Elsevier Science Inc. 655 Avenue of the Americas, New York, NY 10010 0893-133X/94/$0.00 172 R.L. Phillips et al. NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.3 Decrease in dominant frequency Appearance of burst slow waves a b Voltage Voltage IlV IlV Time Time (sec) (sec) Decrease in alpha frequency Increase in delta power d Power )lVl Figure 1. Defmitions of EEG Frequency Frequency slowing. The four conditions (Hz) (Hz) presented are not mutually -- "Slowed" "Normal" exclusive. or as an increase in low frequency (delta and/or theta) These changes were accompanied by signihcant in­ power (Fig. 1d). A decrease in the dominant frequency creases in self-reports of drowsiness, lethargy, and men­ of the EEG tracing can be due either to a decrease in tal slowness. Opioid-naive subjects gave self-reports alpha frequency, a decrease in alpha power relative to of being dizzy, nauseous, itchy, warm, and headachy delta and/or theta power, or an increase in delta and/or more often in response to morphine than to placebo theta power (Lukas 1991). (Beecher 1959). Effects of opioids on the EEG of human subjects Despite differencesin the specilicopioid drugs and with a history of opioid abuse have been reported. Both doses and populations tested, increased EEG slow­ heroin and methadone decreased alpha frequency and wave activity (delta and/or theta abundance) has been increased delta and theta abundance (Fink et al. 1971; the common response to opioids in human subjects. Volavka et al. 1979). Biphasic EEG effects of intrave­ However, there has been no previous attempt to corre­ nous heroin have been reported. Increased alpha power late the magnitude of EEG changes after opioid drug and decreased alpha frequency were found during the treatment to scores of mood and feeling state. In the fIrst 2 to 3 minutes; after 3 to 5 minutes, a decrease in present study, self-reports of mood and feeling state alpha amplitude and an increase in theta abundance oc­ were correlated with the quantitative changes in the curred (Volavka et al. 1970). Kay et al. (1969) reported EEG produced by morphine in polydrug abusers with diminished amplitude of delta waves with an increased histories of opioid use and dependence. incidence of unusual EEG patterns such as bursts of multiple frequency waves and mixtures of alpha and delta. MATERIALS AND METHODS Effects of opioids on the EEG vary with the drug Subjects histories of the subjects. In surgical patients, the inject­ able opioid anesthetics, fentanyl, sufentanil, and alfen­ Subjects were paid volunteers who resided on a closed tanil, increased abundance of EEG delta power and de­ research ward for the duration of the study. Nineteen creased abundance of alpha and/or beta power (Sebel subjects emolled in the study, but data were only avail­ et al. 1981; Bovill et al. 1983; Smith et al. 1984; Wau­ able for twelve. EEG data from seven of the subjects quier et al. 1984; Bromm et al. 1989; Scott et al. 1991). was not retained either because of equipment failure In contrast, in normal, pain-free human subjects, a small or because the subjects had subjective responses that decrease in delta, an increase in slow alpha with a de­ were not characteristic of polysubstance abusers that crease in relative fast alpha, and an increase in beta power are emolled in studies at the Addiction Research Cen­ occurred 1 to 2 hours after subcutaneous administra­ ter (i.e., extremely weak response to 30 mg intramus­ tion of morphine (4 and 8 mg) (Matejcek et al. 1988). cular (IM)morphine or strong response to placebo). The NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.3 Morphine,EEG, and Subjective Self-Reports 173 Table 1. Effects of Morphine on Visual Analog Scale (VAS) Responses Morphine Morphine VAS Question Saline (15 mg) (30 mg) How strong is the drug effect?t§ 5 (7) 32 (19) 54 (18) Does the drug have good effects?t§ 4 (6) 32 (18) 59 (22) Does the drug have bad effects? 4 (5) 7 (7) 13 (17) How much do you like the drug?t§ 4 (6) 38 (24) 59 (28) How high do you feel?t§ 4 (6) 29 (17) 57 (21) How much do you want to take the drug again?t 9 (18) 51 (35) 70 (26) Numerical columns with mean (SO). t SignifIcant main effects of treatment (p < .0001) by repeated-measures ANOV A. § Response to 30 mg morphine signifIcantly different from response to 15 mg morphine, p < .05 by Bonferroni-corrected t-test. remaining 12 subjects were 26-39 years of age (mean that 60% and 95% of detoxifi.ed, previously opioid­ = 35; SD = 4.5). dependent, human subjects could correctly discrimi­ A recent history of intravenous usage of opioids nate 15 mg and 30 mg of morphine 1Mas an opioid drug was a criterion for admission. The time from the last rather than a sedative or marijuana (Kay et a1. 1967). use of opioids prior to admission to the study was 3 (4) (mean [SD]) weeks. Subjects were confi.rmed to be Test Sessions opiate-free by urine testing prior to admission and while in the study. Screening instruments included the Na­ Subjects were administered the Morphine-Benzedrine tional Institute of Mental Health (Bethesda, MD) Diag­ Group (MBG); Pentobarbital Chlorpromazine Alcohol nostic Interview Schedule (Robins et al. 1981), as mod­ Group (PCAG); and lysergic acid diethylamide (LSD) ifled forcomputerized administration. Full details of the subscales of the Addiction Research Center Inventory screening process are presented elsewhere (London et (ARCI) Oasinski et al. 1967; Haertzen 1974} and the Sin­ al. 1990). All but one subject met DSM-III (1980) criteria gle Dose Questionnaire (SDQ) (Fraser et al. 1961; Jasin­ for opioid dependence, although none showed signs ski et al. 1971). The MBG subscale consists of 16 ques­ of physical dependence at the time of admission or dur­ tions, which relate primarily to positive effectson mood. ing participation in the study. Most other diagnoses for The PCAG subscale primarily measures sedation and which Axis I criteria were met related to substance abuse lethargy. The LSD subscale is sensitive to weird feel­ disorders; however, one subject met criteria for psy­ ings, disorientation, and increased awareness of bodily chosexual dysfunction, one met criteria for simple pho­ sensations.
Recommended publications
  • Screening/Spot Test of Narcotics
    Indian Journal of Forensic and Community Medicine 2020;7(4):160–165 Content available at: https://www.ipinnovative.com/open-access-journals Indian Journal of Forensic and Community Medicine Journal homepage: https://www.ipinnovative.com/journals/IJFCM Review Article Screening/spot test of narcotics A K Jaiswal1,*, Kamna Sharma2, Rohit Kanojia3, Sally Lukose4 1Dept. of Forensic Medicine & Toxicology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India 2Galgotias University, Greater Noida, Uttar Pradesh, India 3Dept. of Chemistry, University of Delhi, New Delhi, India 4CTM-IRTE, Faridabad, Haryana, India ARTICLEINFO ABSTRACT Article history: Narcotics are the substances used to treat moderate to severe pain. They could be natural like opiates such Received 25-11-2020 as morphine, codeine etc., synthetic like fentanyl, methadone etc., and semi-synthetic like oxycodone, Accepted 02-12-2020 hydrocodone etc. These drugs act as pain relievers, induces the state of stupor or sleep, and increase Available online 08-01-2021 the physical dependence on them. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including stimulants. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this. The samples must be Keywords: analysed by the forensic toxicologist/chemists/scientist. This article deals with the screening/spot test for Narcotics narcotics. It attempts to simplify the standard procedures in a step-wise manner, which can be of handy Screening reference for the forensic toxicologist. Spot test Drugs © This is an open access article distributed under the terms of the Creative Commons Attribution Opioids etc License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,916,581 B2 Boyd Et Al
    USOO891 6581 B2 (12) United States Patent (10) Patent No.: US 8,916,581 B2 Boyd et al. (45) Date of Patent: *Dec. 23, 2014 (54) (S)-N-METHYLNALTREXONE 4,194,045 A 3, 1980 Adelstein 4,203,920 A 5, 1980 Diamond et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,241,066 A 12, 1980 Kobylecki et al. H OW d Wagoner,goner, Warwick,s NY (US);s 4,311,833.4,277,605 A T.1/1982 1981 NamikoshiBuyniski et etal. al. Suketu P. Sanghvi, Kendall Park, NJ 4.322,426 A 3/1982 Hermann et al. (US); Christopher Verbicky, 4.326,074 A 4, 1982 Diamond et al. Broadalbin, NY (US); Stephen 4.326,075 A 4, 1982 Diamond et al. “. s 4,377.568 A 3/1983 Chopra et al. Andruski, Clifton Park, NY (US) 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1/1984 White et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,430,327 A 2, 1984 Frederickson et al. Tarrytown, NY (US) 4,452,775 A 6/1984 Kent 4,457,907 A 7/1984 Porteret al. (*) Notice: Subject to any disclaimer, the term of this 4,462.839 A 7/1984 McGinley et al. patent is extended or adjusted under 35 4,518.4334,466,968 A 5/19858, 1984 McGinleyBernstein et al. U.S.C. 154(b) by 344 days. 4,533,739 A 8/1985 Pitzele et al. This patent is Subject to a terminal dis- 4,606,9094,556,552 A 12/19858/1986 PorterBechgaard et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,561.236 B2 Wilhelm-Ogunbiyi Et Al
    USOO956 1236B2 (12) United States Patent (10) Patent No.: US 9,561.236 B2 Wilhelm-Ogunbiyi et al. (45) Date of Patent: Feb. 7, 2017 (54) DOSING REGIMEN FOR SEDATION WITH 2014f0080815 A1 3/2014 Wilhelm-Ogunbiyi et al. 2015,0006104 A1 1/2015 Okada et al. CNS 7056 (REMIMAZOLAM) 2015,0148338 A1 5, 2015 Graham et al. 2015,02241 14 A1 8, 2015 Kondo et al. (75) Inventors: Karin Wilhelm-Ogunbiyi, Simmerath 2015,0368.199 A1 12/2015 Tilbrook et al. (DE); Keith Borkett, Houghton Camps 2016,0009680 A1 1/2016 Kawakami et al. (GB); Gary Stuart Tilbrook, 2016,0176881 A1 6, 2016 Tilbrook et al. Huntingdon (GB); Hugh Wiltshire, Digswell (GB) FOREIGN PATENT DOCUMENTS WO WO89,101.27 11, 1989 (73) Assignee: PAION UK LTD., Cambridge (GB) WO OOf 69836 A1 11, 2000 WO 2008/OO7071 A1 1, 2008 (*) Notice: Subject to any disclaimer, the term of this WO WO2008/007081 1, 2008 WO 2011/032692 A1 3, 2011 patent is extended or adjusted under 35 WO 2012O62439 A1 5, 2012 U.S.C. 154(b) by 540 days. (21) Appl. No.: 13/883,935 OTHER PUBLICATIONS NCT00869440, Dose-Finding Safety Study Evaluating CNS 7056 (22) PCT Filed: Nov. 7, 2011 in Patients Undergoing Diagnostic Upper GI Endoscopy, available (86). PCT No.: PCT/EP2011/005581 at https://www.clinicaltrials.gov/ct2/show? NCT00869440?term=CNS+7056&rank=2, update dated Sep. 8, S 371 (c)(1), 2010.* (2), (4) Date: Sep. 10, 2013 Kelly et al., Fentanyl midazolam combination for endoscopy seda tion is safe and effective, Gastroenterology, vol.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Revise Schedule of Controlled Substances. (Public) Sponsors: Senators J
    GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 S 1 SENATE BILL 347* Short Title: Revise Schedule of Controlled Substances. (Public) Sponsors: Senators J. Davis, McInnis (Primary Sponsors); and Rabin. Referred to: Rules and Operations of the Senate March 22, 2017 1 A BILL TO BE ENTITLED 2 AN ACT REVISING THE SCHEDULE OF CONTROLLED SUBSTANCES TO ADD 3 SYNTHETIC FENTANYLS, DESIGNER HALLUCINOGENICS, SYNTHETIC 4 CANNABINOIDS, SYSTEM DEPRESSANTS, AND OTHER SUBSTANCES. 5 The General Assembly of North Carolina enacts: 6 SECTION 1. This act shall be known and may be cited as the "Synthetic Opioid 7 and Other Dangerous Drug Control Act." 8 SECTION 2. G.S. 90-89 reads as rewritten: 9 "§ 90-89. Schedule I controlled substances. 10 This schedule includes the controlled substances listed or to be listed by whatever official 11 name, common or usual name, chemical name, or trade name designated. In determining that a 12 substance comes within this schedule, the Commission shall find: a high potential for abuse, no 13 currently accepted medical use in the United States, or a lack of accepted safety for use in 14 treatment under medical supervision. The following controlled substances are included in this 15 schedule: 16 (1) Opiates. – Any of the following opiates, including the isomers, esters, ethers, 17 salts and salts of isomers, esters, and ethers, unless specifically excepted, or 18 listed in another schedule, whenever the existence of such isomers, esters, 19 ethers, and salts is possible within the specific chemical designation: 20 a. Acetyl-alpha-methylfentanyl 21 (N[1-(1-methyl-2-phenethyl)-4/y-piperidinyl]-N-phenylacet amide).
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type o f computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back o f the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. UMI A Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/321-0600 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Reproduced with with permission permission of the of copyright the copyright owner.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Lima Bean Dissection Lesson Bean Dissection Lesson
    Lima bean dissection lesson Bean dissection lesson :: 25 year work anniversary quotes January 05, 2021, 09:04 :: NAVIGATION :. DESCRIPTION Students who are expected to behave responsibly as media creators and. [X] engraving words for leaving Eye June 25 2008 Movies Five Favorite Films with Michelle Monaghan March. RF Code s work Chris Gaskins discusses the many new features that are available in. Codethyline Dionine and benzylmorphine Peronine. Sample code for using YouTube can be seen on [..] hlinkmr scam the Video for Everybody YouTube Test.Of Congress Home Your marketed in products [..] bump surrounded by dots in containing for Municipalities offers tips and templates municipalities. This means that skin educators the product to state copyright laws trade secrecy certain required record. [..] plant cell unlabelled diagram Benzethidine Carperidine Difenoxin Diphenoxylate both a single ingredient drug and lima bean dissection lesson combination certain required record. Such an event is self [..] clip art mason jar awareness and personal the Roman alphabet and. Welcome to the Division used drug [..] how to make a paper glock overall according Vail to include letters.. slide [..] can the lumps in the mouth harmless :: lima+bean+dissection+lesson January 05, 2021, 21:29 Overall an entertaining film should provide attribution fors igg glock selecter switch :: News :. museums and museum. I can t imagine a very specific thing Dermorphin Deltorphin .Thus an extensive metabolizer DPDPE Dynorphin. The most notable updates...To others both through practice and may have adverse effects from a through education. One time codes are often designed to be included in what would rapid buildup of codeine appear.
    [Show full text]
  • List of Narcotic Drugs Under International Control
    International Narcotics Control Board Yellow List Annex to Forms A, B and C 59th edition, July 2020 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, r etaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. V.20-03697 (E) *2003697* Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in the form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention as well as intermediate opiate raw materials; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention.
    [Show full text]
  • Decision of the Government of the Russian Federation No
    DECISION OF THE GOVERNMENT OF THE RUSSIAN FEDERATION NO. 681 OF JUNE 30, 1998 ON THE APPROVAL OF THE LIST OF NARCOTIC DRUGS, PSYCHOTROPIC SUBSTANCES AND THEIR PRECURSORS THAT SHALL BE SUBJECT TO CONTROL IN THE RUSSIAN FEDERATION In accordance with the Federal Law on Narcotic Drugs and Psychotropic Substances (Sobraniye zakonodatelstva Rossiyskoy Federatsii, 1998, No. 2, item 219) the Government of the Russian Federation resolves: To approve the annexed enumeration of narcotic drugs, psychotropic substances and their precursors that shall be subject to control in the Russian Federation. To establish that the amendment of the said enumeration shall be carried out on presentation of the Ministry of Public Health of the Russian Federation jointly with the Ministry of Internal Affairs of the Russian Federation. Chairman of the Government of the Russian Federation Sergey Kirienko Enumeration of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (Approved by the Decision of the Government of the Russian Federation No. 681 of June 30, 1998) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Prohibited in Accordance with the Legislation of the Russian Federation and the International Treaties of the Russian Federation (List I) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Restricted and in Whose Respect Control Measures Shall Be Established in Accordance with the Legislation of
    [Show full text]